Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PM™, an extended-release formulation of methylphenidate, a ...
as a prescription treatment for ADHD based on a clinical trial, carried out in Japanese children aged six to 17, which showed statistically significant improvements in attention and hyperactivity ...